Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.53 | N/A | -24.69% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.53 | N/A | -24.69% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the competitive landscape and its impact on performance. They did not provide specific guidance for future quarters.
Management highlighted ongoing challenges in the current market environment.
They emphasized the need for strategic adjustments moving forward.
Kodiak Sciences reported a larger-than-expected loss per share, which contributed to a 6.81% drop in stock price following the earnings announcement. The lack of revenue figures and guidance may have added to investor uncertainty. Overall, the company faces challenges that could impact its future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AST SPACEMOBILE INC Class A
Aug 14, 2023